每經AI快訊，昭衍新藥（SH 603127，收盤(pan)價(jia)(jia)：57.65元(yuan)）12月16日(ri)晚間發(fa)布公(gong)(gong)(gong)告(gao)稱，北京昭衍新藥研究中(zhong)(zhong)心股(gu)(gu)(gu)(gu)份(fen)(fen)有(you)限(xian)公(gong)(gong)(gong)司(si)實際控制人之一周志文(wen)(wen)以及(ji)董事左(zuo)從(cong)林(lin)目(mu)前(qian)分別持(chi)(chi)有(you)公(gong)(gong)(gong)司(si)股(gu)(gu)(gu)(gu)份(fen)(fen)約6437萬(wan)股(gu)(gu)(gu)(gu)、約1446萬(wan)股(gu)(gu)(gu)(gu)，持(chi)(chi)股(gu)(gu)(gu)(gu)比例(li)分別為12.02%、2.7%。相關股(gu)(gu)(gu)(gu)份(fen)(fen)來源于首(shou)發(fa)前(qian)限(xian)售股(gu)(gu)(gu)(gu)份(fen)(fen)、公(gong)(gong)(gong)司(si)資本(ben)公(gong)(gong)(gong)積金轉增股(gu)(gu)(gu)(gu)份(fen)(fen)及(ji)股(gu)(gu)(gu)(gu)權(quan)激勵股(gu)(gu)(gu)(gu)份(fen)(fen)等其(qi)他方式。周志文(wen)(wen)擬通(tong)過(guo)上海證券交易(yi)(yi)(yi)所(suo)大(da)宗(zong)交易(yi)(yi)(yi)或集中(zhong)(zhong)競(jing)價(jia)(jia)的(de)方式減(jian)持(chi)(chi)不(bu)超(chao)(chao)過(guo)1100萬(wan)股(gu)(gu)(gu)(gu)，不(bu)超(chao)(chao)過(guo)公(gong)(gong)(gong)司(si)當前(qian)總股(gu)(gu)(gu)(gu)本(ben)的(de)2.05%。周志文(wen)(wen)擬自(zi)本(ben)減(jian)持(chi)(chi)計劃(hua)(hua)(hua)公(gong)(gong)(gong)告(gao)之日(ri)起3個(ge)交易(yi)(yi)(yi)日(ri)后(hou)(hou)的(de)6個(ge)月內(nei)實施(shi)大(da)宗(zong)交易(yi)(yi)(yi)減(jian)持(chi)(chi)；擬自(zi)本(ben)減(jian)持(chi)(chi)計劃(hua)(hua)(hua)公(gong)(gong)(gong)告(gao)之日(ri)起15個(ge)交易(yi)(yi)(yi)日(ri)后(hou)(hou)的(de)6個(ge)月內(nei)實施(shi)集中(zhong)(zhong)競(jing)價(jia)(jia)交易(yi)(yi)(yi)減(jian)持(chi)(chi)。左(zuo)從(cong)林(lin)擬自(zi)本(ben)減(jian)持(chi)(chi)計劃(hua)(hua)(hua)公(gong)(gong)(gong)告(gao)之日(ri)起的(de)3個(ge)交易(yi)(yi)(yi)日(ri)后(hou)(hou)的(de)3個(ge)月內(nei)通(tong)過(guo)上海證券交易(yi)(yi)(yi)所(suo)大(da)宗(zong)交易(yi)(yi)(yi)的(de)方式減(jian)持(chi)(chi)不(bu)超(chao)(chao)過(guo)59萬(wan)股(gu)(gu)(gu)(gu)，不(bu)超(chao)(chao)過(guo)公(gong)(gong)(gong)司(si)當前(qian)總股(gu)(gu)(gu)(gu)本(ben)的(de)0.11%。減(jian)持(chi)(chi)計劃(hua)(hua)(hua)實施(shi)期(qi)間，公(gong)(gong)(gong)司(si)若發(fa)生派發(fa)紅利、送(song)紅股(gu)(gu)(gu)(gu)、轉增股(gu)(gu)(gu)(gu)本(ben)、增發(fa)新股(gu)(gu)(gu)(gu)或配股(gu)(gu)(gu)(gu)等股(gu)(gu)(gu)(gu)本(ben)除權(quan)、除息事項的(de)，減(jian)持(chi)(chi)數(shu)量(liang)將進行相應調整。減(jian)持(chi)(chi)價(jia)(jia)格依據市(shi)場(chang)價(jia)(jia)格確定。

2021年1至(zhi)12月份，昭衍新(xin)藥(yao)的營業(ye)收(shou)入(ru)構成為：藥(yao)物臨床(chuang)前研究(jiu)服務(wu)占(zhan)比97.75%，臨床(chuang)服務(wu)占(zhan)比2.01%，實驗動物及附屬產品銷售業(ye)務(wu)占(zhan)比0.23%。

昭衍(yan)新(xin)藥的(de)董(dong)事(shi)長是馮宇霞，女，58歲，學(xue)歷(li)背景為碩士(shi)；總經理(li)是高大鵬(peng)，男，40歲，學(xue)歷(li)背景為本科。

截(jie)至(zhi)發稿，昭衍新(xin)藥市值為309億元(yuan)。

道達號（daoda1997）“個股趨勢”提醒：
1. 昭衍新藥近30日內北向資金持股量增加348.41萬股，占流通股比例增加0.77%；
2. 近30日內無機構對昭衍新藥進行調研；
3. 昭衍新藥上次發布減持公告是2022年12月13日，第二個交易日上漲1.07%，昭衍新藥近一年共發布22次減持類公告。
更多(duo)個股(gu)趨勢信(xin)息，請搜(sou)索微(wei)信(xin)公眾號“道達號”，回復“查(cha)詢(xun)”，領取(qu)免(mian)費查(cha)詢(xun)權限！

每經頭條(tiao)（nbdtoutiao）——

(記者 陳鵬程)

免(mian)責聲(sheng)明：本文(wen)內容與數據僅供參考(kao)，不構成投資(zi)建議(yi)，使用(yong)前請(qing)核實。據此操作，風(feng)險自擔。